Debt and Its Impacts on TB and HIV Investment
Public financing and domestic resources for health are straining under debt burdens as countries struggle to build up domestic revenues in the face of weak tax systems and volatile markets.
TAG Profoundly Disappointed and Outraged at Lack of Healthcare Protections
Treatment Action Group (TAG) is profoundly disappointed and outraged at the lack of healthcare protections for people living with and affected by HIV, tuberculosis (TB), and hepatitis C (HCV) in the bill to end the US government shutdown.
TAG’s Comments for the September 2025 Meeting of the Advisory Committee on Immunization Practices (Docket No. CDC-2025-0454)
TAG letter urging the Advisory Committee on Immunization Practices (ACIP) to maintain the recommendation of a universal hepatitis B virus (HBV) birth dose vaccine in the United States.
HCV Storyboard: Sibusiso Dlamini
This Hepatitis C virus (HCV) storyboard describes the experience of Sibusiso Dlamini in Tsawne, South Africa. Sibusiso is a young man who began using substances for leisure in high school, and later in life switched to injecting substances for a stronger high.
A Deep Dive Into the HCV Elimination Bill: How Communities Can Secure a Win
TAG is organizing this webinar on July 29 for community organizations and advocates to raise awareness about the HCV Elimination bill, and prepare them to meet and engage with their Senators during the August recess in their district offices or Town Hall meetings.
2024 Annual Report
I’m proud to share with you TAG’s 2024 Annual Report. Last year already seems long ago with all the attacks on research and health care, domestic and international, which are currently taking place under the new administration...
Perspectives of People with HCV Lived Experience and Healthcare Providers on Potential Long-Acting Therapies
This publication discusses findings from two surveys conducted among end users and healthcare providers/policy makers to understand their perspectives on, and the facilitators and barriers to potential long-acting therapies for Hepatitis C virus (HCV) cure currently being developed by the LONGEVITY consortium, funded by the global health agency Unitaid.
LONGEVITY Community Engagement: Perspectives of People with HCV and TB Lived Experience and Healthcare Providers on Potential Long-Acting Therapies
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.
Treatment Action Group Opposes the Nomination of Dr. Jay Bhattacharya for Director of the U.S. National Institutes of Health
The nomination of Dr. Jay Bhattacharya for Director of the United States National Institutes of Health (NIH) continues the pattern of un- and under-qualified nominees put forward by the current administration.
TAG Fiercely Condemns the New Administration’s War on Science
Treatment Action Group (TAG) is disgusted and appalled by the new presidential administration’s flagrant attack on science.